U&I Ventures invests in Autoheal AI Inc.
Funding Provisional 90% confidence first seen
Autoheal AI Inc. raised a $7.9 million seed funding round, with the round led by Innovation Endeavors and participation including U&I Ventures. The investment supports Autoheal’s platform for evaluating and “healing” fleets of AI agents used in software factory workflows, including adding shared context, evaluation infrastructure, and a healer agent that can open Git-verified pull requests under human approval. This matters because it backs infrastructure aimed at scaling and improving enterprise AI agent reliability and security controls.
The deal
Autoheal AI Inc. $7.9M Seed · announced 28 Sep 2026
Investors Innovation Endeavors Emergent Ventures U&I Ventures Param Hansa
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Autoheal AI Inc. announced a $7.9 million seed round led by Innovation Endeavors, with participation from U&I Ventures and others. The company said the funding will expand its platform for evaluating and “healing” fleets of AI agents used in software development workflows, including shared context, evaluation infrastructure, and a healer agent that can open Git-verified pull requests under human approval.
- Why it matters
- For leaders deploying AI agents in engineering workflows, this funding supports a vendor focused on a specific operational gap: making multiple agents more reliable, governable, and auditable at scale. The reported product direction—human-approved Git pull requests, evaluation tooling, and private-cloud training for enterprise-specific models—speaks directly to enterprise concerns around agent quality, change control, and security, which could influence build-versus-buy decisions for AI software delivery infrastructure.
- Evidence
- The coverage comes from a single SiliconANGLE report describing Autoheal’s $7.9 million seed round and the company’s stated product plans. The article consistently attributes the funding details and roadmap claims to the company, but no independent second-source confirmation is provided in the supplied coverage.
- What remains uncertain
- It is not clear from the coverage how mature Autoheal’s platform is today, which enterprise customers, if any, are already in production, or how differentiated its capabilities are versus internal tooling or competing agent-ops platforms. Assumptions about enterprise adoption, security effectiveness, and ROI remain unverified because the report provides funding and roadmap claims rather than deployment results.
- Monitor next
- Watch for concrete proof of enterprise traction such as named customers, production deployments, or published security/control details for the Git-verified, human-approved healer workflow.
Analytical support, not advice — assumptions and open questions stated above.